A new study published in Science Advances details how scientists at the Peter MacCallum Cancer Centre have used the gene editing tool CRISPR-Cas13 to silence cancer-causing gene mutations that were previously untreatable with targeted drugs.

The study highlights the remarkable precision and selectivity of the CRISPR-Cas13 system, which can selectively degrade mutant RNA while sparing healthy RNA. This breakthrough offers the potential for personalized cancer treatments, allowing therapies to be tailored to an individual’s unique genetic profile. Unlike traditional drugs, which often affect both mutated and healthy cells, this method reduces side effects by targeting only the mutated genes. Additionally, the approach overcomes limitations of earlier CRISPR applications, offering greater specificity and paving the way for more effective and safer treatments for aggressive cancers.

Here’s a breakdown of the key findings:

• Targeting RNA: The study used CRISPR-Cas13 to target RNA, the downstream information sent by DNA, instead of DNA itself.
• Mutation-Specific Silencing: By introducing strategic mismatches in the CRISPR guide RNA, the scientists reprogrammed CRISPR-Cas13 to selectively degrade mutant RNA transcripts while sparing the normal, unmutated versions expressed in healthy cells.
• Precision and Adaptability: This approach allows for a high level of precision and flexibility, which can help to reduce side effects.
• Personalized Treatments: This system could lead to personalized cancer treatments tailored to an individual’s unique genetic profile.
• Overcoming Limitations: The research overcomes limitations of previous therapeutic applications of CRISPR by blocking only the mutated forms of the genes.
• Lab Setting: The method has been demonstrated in a lab setting, and more research is needed before it can be tested in people.

This work demonstrates the potential of CRISPR-Cas13 to act as a precise, mutation-specific drug, opening new avenues for treating cancers driven by hard-to-target mutations. The study authors emphasize that this method can silence single-nucleotide variants (SNVs) with an unprecedented level of accuracy and flexibility.

Source.